{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:51:11Z","timestamp":1789145471361,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metabolic dysfunction-associated steatohepatitis (MASH) is a highly prevalent liver disease that can progress to cirrhosis and hepatocellular carcinoma. Despite its growing clinical burden, effective therapies remain limited. Daixie recipe (DXR), derived from\n                      <jats:italic>Danggui Shaoyao San<\/jats:italic>\n                      in\n                      <jats:italic>Jingui Yaolue<\/jats:italic>\n                      , has shown notable clinical efficacy in treating MASH, yet its underlying pharmacological mechanisms remain to be clarified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To clarify the pharmacological effects of DXR and to elucidate the underlying mechanisms of DXR for treating MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      UHPLC-Q-Orbitrap HRMS was used to identify the phytochemcials in DXR. The key targets and ingredients for combating MASH were explored by using a suite of\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      experiments, as well as molecular dynamics simulations and bioinformatics analysis. The MASH model was established in C57BL\/6 male mice by feeding either a high-fat, high-fructose, high-cholesterol diet or a methionine- and choline-deficient (MCD) diet. ELISA and Western Blotting were used to measure liver tissue pathology, serum biochemistry, lipid synthesis enzymes, oxidative stress markers, pro-inflammatory mediators, apoptosis-related factors, and\n                      <jats:italic>p<\/jats:italic>\n                      -AKT1, Nrf2, and HO-1 expression. The effects of DXR on the PI3K\/AKT pathway and Keap1\/Nrf2 signaling were analyzed in free fatty acid-induced AML12 cells and HEK293-Nrf2-Luc cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DXR shows significant therapeutic efficacy in ameliorating hepatic steatosis and inflammation, as evidenced by the marked reduction in the levels of serum biomarkers (such as ALT, AST, TG, TC, and LDL-c). Phytochemcial analysis coupling with network pharmacology analyses identify key targets of DXR for treating MASH, including AKT1, EGFR, TP53, STAT3, and IL6, with biological processes related to oxidative stress. Further investigations show that DXR significantly up-regulates p-AKT1, Nrf2, and HO-1, suggesting that this recipe activates both the PI3K\/AKT and Keap1\/Nrf2 signaling pathways. It is also found that DXR down-regulates the expression levels of key lipogenic enzymes (such as FASN, SCD1, and ACC1) but upregulates CPT1a in hepatocytes. DXR also exhibits significant antioxidant and anti-inflammatory effects, as demonstrated by a marked reduction in MDA levels and inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, and IL-6), along with the increased activity levels of both SOD and GSH-Px. Additionally, DXR reduces hepatocyte apoptosis by up-regulating Bcl-2 and down-regulating Bax. Molecular dynamics simulations and luciferase reporter assays show that four flavonoids in DXR are key active constituents to activate the PI3K\/AKT and Keap1\/Nrf2 signaling pathways. Specifically, quercetin promotes AKT1 phosphorylation, while four flavonoids activate Nrf2 signaling, with apigenin exhibiting the most potent effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DXR effectively ameliorates MASH in a mouse model by reducing hepatic steatosis, inflammation, and oxidative stress. Its mechanism of action involves the suppression of lipid synthesis and the prevention of hepatocyte apoptosis, achieved by modulating key anti-inflammatory and antioxidant signaling pathways. Flavonoids (such as apigenin and quercetin) are identified as the key active ingredients in DXR responsible for activating Keap1\/Nrf2 and PI3K\/AKT signaling pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1772033","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:21Z","timestamp":1773379521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Daixie recipe ameliorates diet-induced MASH in mice via activating PI3K\/AKT and Keap1\/Nrf2 signaling"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoli","family":"He","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"You","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Deng","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Traditional Chinese Medicine (TCM) Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiren","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Zhuanqiao Community Health Service Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Qi","sequence":"additional","affiliation":[{"name":"Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Traditional Chinese Medicine (TCM) Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Ge","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Traditional Chinese Medicine (TCM) Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011037","article-title":"Astaxanthin prevents diet-induced NASH progression by shaping intrahepatic immunity","volume":"22","author":"Yang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"MaChado","year":"2016","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117383","article-title":"Bile acids metabolism involved in the beneficial effects of Danggui Shaoyao San via gut microbiota in the treatment of CCl4 induced hepatic fibrosis","volume":"319","author":"Zhao","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115736","article-title":"Danggui Shaoyao San ameliorates the lipid metabolism via the PPAR signaling pathway in a Danio rerio (zebrafish) model of hyperlipidemia","volume":"168","author":"Wang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.671708","article-title":"Danggui-shaoyao-san improves gut microbia dysbiosis and hepatic lipid homeostasis in fructose-fed rats","volume":"12","author":"Yin","year":"2021","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12263-015-0495-x","article-title":"Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice","volume":"10","author":"Ann","year":"2015","journal-title":"Genes Nutr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S304817","article-title":"Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease","volume":"14","author":"Liang","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e15810","DOI":"10.1111\/jfpp.15810","article-title":"Isolation and identification of squalene as an antioxidative compound from the fruits of Prunus mume","volume":"45","author":"Kim","year":"2021","journal-title":"J Food Process Preserv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1575106","article-title":"Hydrogen gas (H2) delivered by intraperitoneal injection alleviated methionine- and choline-deficient diet-induced metabolic dysfunction--associated steatotic liver disease in mice via inhibiting GSDMD- and GSDME-mediated pyroptosis","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2016.1259983","article-title":"Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment","volume":"58","author":"Russo","year":"2018","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e143690","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X13500560","article-title":"Ligusticum chuanxiong prevents ovariectomy-induced liver and vascular damage in rats","volume":"41","author":"Li","year":"2013","journal-title":"Am J Chin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8888040","article-title":"Efficacy and mechanism of a chinese classic prescription of yueju in treating nonalcoholic steatohepatitis and protecting hepatocytes from apoptosis","volume":"2020","author":"He","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00832-w","article-title":"Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis","volume":"20","author":"Sharma","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104451","article-title":"Future potential therapeutics to treat MASH","volume":"30","author":"Mahajan","year":"2025","journal-title":"Drug Discov Today"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13020-023-00761-5","article-title":"Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design","volume":"18","author":"Chen","year":"2023","journal-title":"Chin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-025-04052-w","article-title":"Lipogenesis and MASLD: re-thinking the role of SREBPs","volume":"99","author":"Nakagawa","year":"2025","journal-title":"Arch Toxicol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12944-022-01726-7","article-title":"WY-14643 attenuates lipid deposition via activation of the PPAR\u03b1\/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC","volume":"21","author":"Wang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1053\/j.gastro.2020.06.031","article-title":"IRE1A stimulates hepatocyte-derived extracellular vesicles that promote inflammation in mice with steatohepatitis","volume":"159","author":"Dasgupta","year":"2020","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH -- role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5080843","article-title":"Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis","volume":"2019","author":"Peng","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11033-024-09771-4","article-title":"Regulation of Keap1-Nrf2 signaling in health and diseases","volume":"51","author":"Xiao","year":"2024","journal-title":"Mol Biol Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.92337","article-title":"NUP85 alleviates lipid metabolism and inflammation by regulating PI3K\/AKT signaling pathway in nonalcoholic fatty liver disease","volume":"20","author":"Wu","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1186\/s12967-024-05621-w","article-title":"VEGFB ameliorates insulin resistance in NAFLD via the PI3K\/AKT signal pathway","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.037","article-title":"Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis","volume":"74","author":"Mohs","year":"2021","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12944-024-02220-y","article-title":"Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Jin","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156341","article-title":"Sappanone A alleviates metabolic dysfunction-associated steatohepatitis by decreasing hepatocyte lipotoxicity via targeting Mup3 in mice","volume":"136","author":"Zhu","year":"2025","journal-title":"Phytomedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1767063","article-title":"An up-to-date overview of computational polypharmacology in modern drug discovery","volume":"15","author":"Chaudhari","year":"2020","journal-title":"Expert Opin Drug Discov"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1772033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:23Z","timestamp":1773379523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1772033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1772033"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1772033","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1772033"}}